Coburn RF. The measurement of endogenous carbon monoxide production. J Appl Physiol 112: 1949 -1955, 2012. First published March 22, 2012 doi:10.1152/japplphysiol.00174.2012.-Recent findings that heme oxygenase-1 can be induced by oxidative stress and inflammation in many different cellular systems, and that carbon monoxide (CO) produced as a by-product of this enzyme is a signaling molecule, have generated a major research area with hundreds of studies published over the last few years. The measurement of expired CO concentration has been used in humans as a biomarker of induced heme oxygenase resulting from inflammation or oxidative stress, but a precise method of measuring endogenous CO production that can be easily used to study patients is needed. The present study describes such a method. The described method allows calculation of the rate of heme catabolism with a precision of Ϯ2 mol/h, ϳ10% of the mean normal rate in subjects used in this investigation. This method, which is subject-patient friendly, precise, and inexpensive to perform, should be applicable to studies performed on humans with induced heme oxygenase and studies of effects of therapy for inflammatory and hemolytic diseases. heme oxygenase; inflammation; hemolytic anemia; asthma SJOSTRAND WAS THE FIRST TO obtain evidence that carbon monoxide (CO) is endogenously formed in humans, following his observations that, in normal humans, CO concentrations ([CO]) in expired air were larger than those in inspired air (26), and that venous blood carboxyhemoglobin (COHb) were elevated in patients with hemolytic anemia (25). Ludwig et al. (13) reported that nonenzymatic, chemical oxidation of hemoglobin resulted in formation of CO, but did not determine that this resulted from heme oxidation. Endogenous CO production (V CO) was shown to originate from the ␣-methene carbon atom of the heme moiety; it is formed in a mole-to-mole ratio during heme catabolism (6). The rate of endogenous V CO was measured by preventing pulmonary CO excretion and measuring rates of increases in venous blood COHb, which allowed calculation of rates of increases in the total body CO stores (3). With this method (the Hood-COHb Method), CO excretion was prevented by having the subject breath for 2-3 h in a small hood, which was sealed at the neck and into which O 2 was added and CO 2 absorbed. The concept that, under conditions where CO excretion is prevented, rates of increases in total body CO stores are equal to the V CO follows the finding that the rate of CO catabolism in humans is very small (14). The V CO in 10 normal young male subjects at rest averaged 0.42 Ϯ 0.07 ml/h (STPD), and calculations that assumed average 120-day erythrocyte life spans indicated that catabolism of hemoglobin in mature erythrocytes could explain ϳ80% of this value. Endogenous V CO paralleled bilirubin turnover, a finding that supported mole-mole CO formation-heme degradation (1, 12). V CO measurements in patients with hemolytic anemia accurately predicted erythrocyte survival times measured using the 51 Cr-labeled method (5). Some of the unexplained V CO could originate in the bone marrow during erythropoiesis (29) and is known to result from rapid turnover of heme, catalyzed by heme oxygenases. This concept was supported by the finding that, after administering glycine-2-14 C to normal humans, early peaks of radioactive 14 CO preceded the major 14 CO peak (29).
SJOSTRAND WAS THE FIRST TO obtain evidence that carbon monoxide (CO) is endogenously formed in humans, following his observations that, in normal humans, CO concentrations ([CO]) in expired air were larger than those in inspired air (26) , and that venous blood carboxyhemoglobin (COHb) were elevated in patients with hemolytic anemia (25) . Ludwig et al. (13) reported that nonenzymatic, chemical oxidation of hemoglobin resulted in formation of CO, but did not determine that this resulted from heme oxidation. Endogenous CO production (V CO) was shown to originate from the ␣-methene carbon atom of the heme moiety; it is formed in a mole-to-mole ratio during heme catabolism (6) . The rate of endogenous V CO was measured by preventing pulmonary CO excretion and measuring rates of increases in venous blood COHb, which allowed calculation of rates of increases in the total body CO stores (3) . With this method (the Hood-COHb Method), CO excretion was prevented by having the subject breath for 2-3 h in a small hood, which was sealed at the neck and into which O 2 was added and CO 2 absorbed. The concept that, under conditions where CO excretion is prevented, rates of increases in total body CO stores are equal to the V CO follows the finding that the rate of CO catabolism in humans is very small (14) . The V CO in 10 normal young male subjects at rest averaged 0.42 Ϯ 0.07 ml/h (STPD), and calculations that assumed average 120-day erythrocyte life spans indicated that catabolism of hemoglobin in mature erythrocytes could explain ϳ80% of this value. Endogenous V CO paralleled bilirubin turnover, a finding that supported mole-mole CO formation-heme degradation (1, 12) . V CO measurements in patients with hemolytic anemia accurately predicted erythrocyte survival times measured using the 51 Cr-labeled method (5) . Some of the unexplained V CO could originate in the bone marrow during erythropoiesis (29) and is known to result from rapid turnover of heme, catalyzed by heme oxygenases. This concept was supported by the finding that, after administering glycine-2- 14 C to normal humans, early peaks of radioactive 14 CO preceded the major 14 CO peak (29) .
Heme oxygenase-1 (HO-1) is induced as a result of oxidative stress and inflammation, and CO, one of its by-products, can function in signaling (18, 21, 31) , which triggers a cytoprotective response. These findings have been taken a step further in experiments that test the efficacy of CO therapy (17, 21) . Animal studies have shown promising effects of CO therapy on inflammatory conditions, such as graft rejection, rheumatoid arthritis, pulmonary hypertension, colitis, airway hyperresponsiveness, liver failure, hemorrhagic shock, and autoimmune diseases (17) . The goal of the present study, to develop a subject-friendly and relatively easy, inexpensive, and precise method of measuring V CO, responds to the need for such a method to help extend some of these findings to humans.
Endogenous V CO in humans resulting from induced HO-1 during inflammation or oxidative stress or hemolytic anemia has been assessed with measurements of the [CO] in expired air usually corrected for the [CO] in ambient air (8, 16, 19, 22, 27, 28, 32) . These publications, and others not cited here, reported two-to fourfold increases in expired [CO] in patients with various inflammatory diseases, hemolytic anemia, and critically ill patients. [The publication by E. O. Owens (18) nicely summarizes some of these results.] The expired [CO] measurement is extremely valuable in screening, but does not produce precise measurements of V CO (or the rate of heme turnover). As will be discussed later in this paper, the [CO] in expired gas is determined by multiple physiological variables, as well as endogenous V CO rates.
The method of measuring V CO described in this paper overcomes the difficulty of prolonged breathing in a small hood and does not require venous blood samples or COHb analyses. The precision of V CO measurements is increased compared with measurements using the Hood-COHb Method, and in normal subjects measurements can be obtained in a 90-min study.
METHODS
The method of measuring V CO described here prevents pulmonary CO excretion and uptake by matching room air PCO to the PCO in mean pulmonary capillary blood (mean capillary PCO). Under this condition, rates of increase in total body CO stores resulting from endogenous V CO are determined by measuring rates of increases of mean capillary PCO over a time period of ϳ90 min. The relationship of the rate of increase in mean capillary PCO to the rate of increase in total body CO stores is determined (calibrated) by measuring effects on mean capillary PCO of administering a known quantity of CO.
How Room Air PCO Is Controlled
An 8-by-10 ft room was sealed by converting it into a room-tent using plastic sheets attached by tape to walls and the floor. The total volume of air in this room is 540 ft 3 . Room air was mixed with a powerful fan turned on for 10 s as needed. The room [CO], constantly monitored as described below, could be controlled to Ϯ0.03 ppm (Ϯ2 ϫ 10 Ϫ5 mmHg PCO), and after mixing was stable except for a small leak (1-2% per 10 min). Increases in room air [CO] or corrections for the small leak were effected by manually injecting small amounts of CO from a syringe, followed by fan mixing. Example: an injection of 2-ml CO increased room air [CO] 0.14 ppm (1.1 ϫ 10 Ϫ4 mmHg).
[CO] units used are as follows: ppm for describing gas [CO] ; PCO in mmHg was used when describing mean capillary CO or the matching of air and mean capillary PCO.
How Mean Capillary PCO Is Measured
This follows investigations that established there is a correlation between alveolar PCO, measured after 20 -30 s of breath holding or rebreathing, and venous blood COHb (7, 10, 11, 23) . The goal of this approach is to achieve a state where mixed alveolar PCO is equal to mean capillary PCO, i.e., no net CO transfer occurs between capillary blood and alveolar air. Thus mean capillary PCO can be determined with measurements of mixed alveolar gas PCO. In the present study, the rebreathing approach was chosen because there is more efficient lung gas mixing than during breath holding (11) . Modifications of the rebreathing method were made as follows. 1) The rebreathing bag ϩ lung gas PO2 was kept nearly constant during rebreathing. 2) Rebreathing was started under a condition in which the PCO in air in the rebreathing bag was set to nearly match mean capillary PCO measured in the previous rebreath run. 3) Mean capillary PCO measurements were normalized to a given mixed alveolar PO2.
The O2-clamp method. A potential problem is that, when the rebreathing bag initially contained air, during rebreathing there were steep decreases in rebreathing bag ϩ lung PO2; therefore, [CO] measurements in gas collected after rebreathing were made during an O2 transient. This problem was solved by controlling the rebreathing bag ϩ lung gas PO2 during rebreathing. Using a trial and error approach during the first two rebreaths, the PO2 of the gas in the rebreathing bag was adjusted before rebreathing to a value that, after mixing with lung gas early during rebreathing, was estimated to produce a mixed alveolar gas PO 2 of ϳ110 Torr. During rebreathing, 100% O 2 was added to rebreathing bag at 200 -300 ml/min. These settings usually produced a PO 2 in gas collected after rebreathing of ϳ110 Torr. For the second rebreath, the rate of O 2 administration was finely adjusted to produce a PO 2 in collected gas of 100 Torr. These settings were then used in all subsequent rebreaths. Subjects (wearing a nose clip) expired to expiratory reserve volume (the lung volume at the end of a normal breath). Subjects then inserted a mouth piece connected to a 3-liter latex rebreathing bag (A-M Systems, Carlsborg, WA) that contained 30 ml gas/kg body wt, inspired emptying the rebreathing bag, and then inspired-expired every 1 s for time periods of 10 -40 s. At the end of the rebreathing maneuver, subjects exhaled fully into the rebreathing bag (to residual volume). The collected mixed alveolar gas was analyzed for PCO and PO2. Figure 1 illustrates time-dependent changes in PCO and PO2 during rebreathing using the O 2-clamp method, comparing protocols where the rebreathing bag PCO was initially set at a low value found in ambient air in my laboratory, and where the PCO of the rebreathing bag gas initially was matched to mean capillary PCO determined in the previous run. The finding that mixed alveolar PCO increased to maximal values after 30 s of rebreathing using either protocol indicates equilibrium had been achieved between mixed alveolar gas and mean capillary PCO. In addition, this figure shows that increasing rebreathing bag gas PCO to approach levels in mean capillary blood before rebreathing resulted in a shortening of the rebreathing time required to achieve equilibrium. Thus this latter approach was used during V CO measurements made in this study.
The PCO 2 in gas collected after 30 s of rebreathing were in the range of 46 -48 Torr. During rebreathing, lung ϩ rebreathing bag PCO2 is known to rapidly increase until it reaches equilibrium with mixedvenous PCO2 (usually ϳ47 Torr in resting humans) (2). This is followed by small increases resulting from increases in mixed-venous PCO2, resulting from CO2 formation. These changes in alveolar PCO2 do not alter the equilibrium between mean capillary PCO and mixed alveolar PCO.
Normalizing mean capillary PCO values to a given mixed alveolar gas PO 2. In previous studies that developed the breath-holding and rebreathing methods of measuring mixed alveolar PCO, cited above, effects of alveolar PO2 changes on alveolar PCO were not studied. However, the mean capillary PCO is partially determined by the mean capillary PO2 following the classical assumption described by the Haldane equation: PCO ϭ COHb ϫ PO2/O2Hb ϫ 220, where 220 is the equilibrium constant for the reaction of O2 ϩ COHb ↔ CO ϩ O2Hb, and PO2 and O2Hb represent mean capillary values (4, 9) . COHb is assumed to remain constant during pulmonary capillary blood flow. Although the O 2-clamp method controlled the rebreathing bag ϩ lung gas PO2, there were still small PO2 differences in different gas samples collected after rebreathing. The precision of the mean capillary PCO measurement was increased by normalizing PCO values to a given PO2, usually 100 Torr. Figure 2 illustrates the PO2 sensitivity of the mean capillary PCO measurement. At a mean capillary PCO of 1 to 2.5 ϫ 10 Ϫ3 mmHg, the usual baseline range found in normal subjects used in this study, the normalization factor obtained from plots shown in Fig. 2 is 1.5 ϫ 10 Ϫ5 mmHg PCO per Torr PO2. This value was used in normalizing mean capillary PCO values in the present study.
Administration of CO
CO was administered to calibrate the relationship of measured increases in mean capillary PCO to increases in total body CO stores resulting from endogenous V CO. CO administration was also used in the V CO simulation experiments described below. First, 5 ml CO were added to 1,500 -1,800 ml of air in a rebreathing bag. Subjects then Fig. 1 . The time dependence of increases of PCO in mixed alveolar gas collected using the O2-clamp rebreathing method. Open squares indicate data obtained when air in the rebreathing bag before rebreathing contained a PCO of 1.8 ϫ 10 Ϫ4 mmHg. Solid squares indicate data obtained when the rebreathing bag PCO before rebreathing was nearly matched to a mean capillary PCO (in this case 2.0 ϫ 10 Ϫ3 mmHg), the protocol used in measuring CO production (V CO) in the present study. These data were obtained on the same subject on different days, which explains why mean capillary PCO values equal to the mixed alveolar PCO values measured at 30 s of rebreathing were different. Mixed alveolar PO2 data plotted in this figure illustrate the efficiency of clamping PO2 during rebreathing. Data were replicated in 4 additional experiments.
rebreathed gas in this bag for 30 s, as described above. The [CO] of collected gas was measured, allowing calculation of the quantity of CO absorbed during rebreathing; in most subjects Ͼ98% of the CO originally in the rebreathing bag was absorbed. Most of the absorbed CO mixes in the blood as COHb. In normal humans, 12-16% of the total body CO stores are extravascular (14) , bound to myoglobin and other hemoproteins. A very small portion of the total body CO store is dissolved in blood and body tissues. It is reasonable to assume that the distribution of administered CO is the same as distribution of CO produced via endogenous production. In resting humans, complete mixing of administered CO occurs within 10 min (14) .
V CO Measurements
1) Subjects performed a 30-s rebreathing maneuver, as described above. Collected gas was analyzed to obtain a mean capillary PCO.
2) The room-tent air PCO was increased to match this measured mean capillary PCO. 3) Room-tent air was used to add 30 ml gas/kg body wt to the rebreathing bag for the next run; then the subjects rebreathed as above for 30 s. 4) This sequence was repeated every 6 -10 min for a total of ϳ90 min. 5) Then, to obtain a dilution factor, 5 ml of CO were administered, as described above, and, after a 10-min time period to allow mixing in body stores (14) , the resultant increase in mean capillary PCO (1PCO) was measured using the rebreathing method. V CO was calculated to equal to the rate of increase in mean capillary PCO/h (JPCO), multiplied by the dilution factor equal to 5, divided by 1PCO; i.e., V CO ϭ JPCO ϫ 5/1PCO. V CO values are given as STPD.
Matching of Room-Tent Air PCO to Mean Capillary PCO to Prevent CO Excretion or Uptake
In a steady state, CO excretion from a lung that has even alveolar ventilation-to-perfusion and alveolar ventilation-to-diffusing capacity ratios is effected by two processes (4): 1) diffusion of CO from capillary blood into alveolar gas, determined by the PCO gradient and the diffusing capacity; and 2) excretion of alveolar CO determined by the alveolar ventilation rate. There are two relevant PCO gradients, across the alveolar membrane and alveolar minus ambient air. Matching air and mean capillary PCO abolishes both gradients. However, in matching room-tent air PCO to mean capillary PCO, air PCO must be corrected for dilution due to humidification of inspired air. Therefore "matching" as described in this paper requires a room-tent air PCO to be 7% greater than mean capillary PCO. Respiratory quotient effects also slightly dilute inspired PCO; however, this effect is insignificant (4).
Simulation of V CO
CO (0.5-1.0 ml) was administered, as described above, to the subject every 15-20 min. After each administration, the resulted increase in mean capillary PCO was measured using the rebreathing procedure. Three V CO simulation experiments were performed.
Total Body Hemoglobin Measurements
These measurements were obtained using the method of Sjostrand (24) .
Subjects
See Table 1 . Ten male nonsmokers were studied. There was no history of anemia, asthma, or other inflammatory diseases in any of these subjects, and they had not donated blood or taken medications. Subjects reported that normal physical examinations and blood measurements had been performed within 2 yr before the study. Their total body hemoglobin (TBHgb) contents were in the normal range. Seated subjects were studied at rest after a midday lunch. They had not performed strenuous exercise before the study. Responsibilities of the subjects were to rebreath for 30 s every 6 -10 min. The subjects usually read a book in between rebreaths. Research was carried out according to the principles of the Declaration of Helsinki. Informed consent was obtained. This project was approved by the Institutional Review Board of the University of Pennsylvania.
[CO] and PO 2 Measurements
Mixed alveolar [CO] was analyzed in a model 48i infrared gas filter correlation CO analyzer (Thermo Fisher Scientific, Franklin MA). The output was linear (Ϯ0.1%) over [CO] 1-100 ppm. This analyzer was engineered so that its output was not influenced by the presence of other gases, including water vapor and nitric oxide. But it still had a very small sensitivity to CO 2 (0.006 ppm/mmHg), which, in some experiments, required a correction. The precision of the [CO] measurement determined from 20 duplicate analyses was Ϯ0.03 (SD) ppm, and there was a Ͻ1% output drift in 3 h. This analyzer was operated during a constant gas flow, which was set at 960 ml/min. During each experiment, a CO standard (2-4 ppm) was analyzed every 30 min. An O 2 analyzer (Max O2 from Mastec, Salt Lake City, UT) was placed in series with the CO analyzer. The output was calibrated with gases at known O2 concentrations and had a precision of Ϯ0.1%. Sixty five seconds for the CO analyzer and 20 s for the O2 analyzer were required to reach steady values. However, this slow response was not a problem in the present experiments, where 1,500 -1,800 ml of gas collected after rebreathing were directed through these analyzers at a flow rate of 960 ml/min, until a steady value was obtained. TBHgb, total body hemoglobin. Fig. 2 . The O2 sensitivity of the mean capillary PCO measurement using the O2-clamp rebreathing method. Subjects rebreathed for 30 s and then expired into the rebreathing bag. In different runs, the PO2 initially in gas in the rebreathing bag was changed by addition of small amounts of O2 or N2 or by changing the O2 flow rate into the rebreathing bag during rebreathing. Expired gas was analyzed for PO2 and PCO. This figure shows data obtained in 2 subjects. These were identical to data found in an additional 3 subjects. These data allow normalization of mixed alveolar gas PCO values to a given mixed alveolar gas PO2. Figure 3 shows a result of an experiment where V CO was simulated by adding CO to the body stores every 20 min and then determining the resultant increase in mean capillary PCO. These data show linearity and the precision of the mean capillary PCO measurement and are typical of results found in two other experiments. The simulated V CO calculated by multiplying evoked increases in mean capillary PCO by dilution factors matched within 5% the administered CO rate. Results indicate that the O 2 -clamp rebreathing method can precisely track a simulated V CO. Figure 4 shows a plot of increases in mean capillary PCO vs. time, typical of findings in 9 of the 10 subjects where the rate of mean capillary PCO increase was constant over 90 -100 min.
RESULTS

Simulated V CO
The Measurement of V CO
(There is a possibility that small endogenous V CO cycles occurred during this study.) The ability to match air and mean capillary PCO is also illustrated in this figure. In 10 subjects, deviations of single air PCO values from regression lines drawn through mean capillary PCO data ranged from 0 to 2 ϫ 10 Ϫ5 mmHg. In five studies, the difference between air and mean capillary PCO was experimentally changed every 30 min, as a square wave, and effects on rates of increases in mean capillary PCO determined. Effects on slopes of regression lines obtained by plotting mean capillary PCO vs. time could not be detected when room-tent air-mean capillary PCO differences were Ͻ7.6 ϫ 10 Ϫ5 mmHg. These data establish an air-mean capillary PCO matching requirement for this method. Table 2 lists results of the V CO measurements. In 9 of the 10 subjects in whom rates of increases in mean capillary PCO were constant, V CO were calculated from data collected over the 90-to 100-min study. In one subject, CB, the rate of increase in mean capillary PCO declined over the first 50 min of the study; data listed here were taken from measurements made over the last 40 min of the study. The mean V CO found in these subjects, 0.43 Ϯ 0.08 ml/h STPD, is identical to values reported in our original study that used the Hood-COHb Method (3); i.e., 0.42 Ϯ 0.07 ml/h STPD, and to results reported by Lynch and Moede (15) . V CO values in this table are also normalized to TBHgb and body weight. The mean V CO/kg is not significantly different from values reported in our original study, but the mean V CO/TBHgb is smaller in the present study.
Was the new method more precise than the Hood-COHb Method? With the new method, the mean deviation of single mean capillary PCO values from regression lines, 2.0 ϫ 10 Ϫ5 mmHg (N ϭ 30) converted to COHb using the Haldane equation, corresponded to 0.004 COHb %saturation. With the Hood-COHb Method, the mean deviation of a single measurement was 0.038% saturation (3) . From this comparison it is concluded that the mean capillary PCO measurement is an order of magnitude more precise than the COHb measurement. Because of this, the slopes of lines plotting increases in mean capillary PCO vs. time can be measured with much greater precision. The ease in obtaining mean capillary PCO values allowed us to plot slopes using 10 -12 data points, increasing the precision of the measurement. Considering both errors involved measuring the dilution factor and the rate of increase in mean capillary PCO over ϳ90 min, V CO can be measured in a normal subject with a precision of Ϯ10% (SD). The time duration required for this measurement depends on the V CO magnitude. With hemolytic anemia patients, in whom V CO was as much as eight times higher than values found in normal subjects (5), the study can be completed in as short a time as 20 min after air and mean capillary PCO are matched. If the twoto threefold increases in expired [CO] reported in patients with various inflammatory diseases, cited above, are due to two-to threefold increases in V CO, it should be possible to measure V CO in these patients in a 40-to 60-min study. Figure 5 shows multiple V CO measurements made on a single subject over a time period of 13 mo. The variation in V CO values seen here is similar to that described previously for single subjects studied three to four times by Lynch and Moede (15) and establishes that the variation found by Lynch and Moede was not entirely due to experimental errors. In the present study, the differences in measured V CO between different subjects [Ϯ0.08 (SD) ml/h] are similar to the variation Fig. 3 . A simulated V CO can be measured using the method described in this paper. CO was administered every 20 min, and resultant increases in mean capillary PCO were determined. Fig. 4 . Increases of mean capillary PCO performed under conditions where room-tent air and mean capillary PCO were matched. In this experiment, performed on subject JC, PCO increased at a rate of 1.14 ϫ 10 Ϫ4 mmHg/h, and calculated V CO was 0.35 ml/h (STPD).
found with multiple measurements of V CO in a single subject, i.e., Ϯ 0.07 ml/h. Thus differences in measured V CO between different subjects, given as V CO/TBHgb or V CO/kg, may primarily be due to diurnal or day-to-day V CO cycles.
DISCUSSION
This paper describes a more rapid, precise, and subjectfriendly method of measuring endogenous V CO in humans than previously available. It is based on 1) matching air and mean capillary PCO, thereby preventing pulmonary CO uptake or excretion; and 2) a method of measuring rates of increase in the body CO stores by making measurements of mean capillary PCO. The measurement of mean capillary PCO is used to match both air and mean capillary PCO values, and to determine increases in total body CO stores resulting from endogenous V CO. Rebreathing-timing experiments indicated that equilibrium between mixed alveolar and mean capillary PCO is easily achieved in normal subjects, a requirement for being able to determine mean capillary PCO with measurements of mixed alveolar PCO. I emphasize the importance of starting the rebreathing maneuver under conditions where the PCO in the gas in the rebreathing bag is nearly equal to mean capillary PCO.
Before the onset of rebreathing, alveolar PCO is already nearly matched to room-tent air PCO, even in alveoli that have low ventilation-to-perfusion or low ventilation-to-diffusing capacity ratios. Thus, during rebreathing, only a small CO transfer out of capillaries into alveoli is required for mixed alveolar PCO to approach equilibrium with mean capillary PCO. Results of the V CO simulation experiments validated the use of mean capillary PCO measurements to determine increases in body CO stores. The mean V CO value found in the 10 normal subjects studied using the new method is identical to values previously published. Patient-to-patient variation and the variation in V CO measured in one subject over 13 mo are also similar to results published previously (15) . The mean V CO, 0.43 ml/h, measured using the new method corresponds to a rate of heme degradation of 19 mol/h (see the APPENDIX).
The precision of the mean capillary PCO measurement was increased by three modifications of originally described rebreathing protocols: 1) the use of the O 2 -clamp method; 2) the matching of PCO in the rebreathing-bag gas before onset of rebreathing to mean capillary PCO obtained in the previous rebreathing run; and 3) the normalization of measured PCO to correct for small variations of PO 2 in different gas samples collected after 30-s rebreathing maneuvers. The mean capillary PCO normalization requires that the mean alveolar PO 2 be estimated. In this study, 100 mmHg were used, and normalization changes in mean capillary PCO were usually small, 1 to 7 ϫ 10 Ϫ5 mmHg PCO. Errors in this estimate do not change calculated rates of increase of mean capillary PCO or the calculated V CO, but can cause error in matching room-tent air PCO to mean capillary PCO. An error of 5 Torr between estimated and actual alveolar PO 2 could result in a mismatch of 7.5 ϫ 10 Ϫ5 Torr, a mismatch that was experimentally shown not to be critical in influencing the change of mean capillary PCO with time. Whether or not this error could become significant if this method is used in subjects with lung diseases needs to be studied.
As cited in the Introduction, currently a commonly used method of assessing endogenous V CO involves measurements of expired [CO] . The method described in the present study has some advantages compared with the expired [CO] method. 1) It gives a quantitative result in milliliters CO produced per hour or conversion to the rate of heme catabolism per hour.
2) It is precise, can detect Ϯ2 mol heme catabolism/h. 3) It is not influenced by some of the uncertainties inherent in the use of the expired [CO] measurement. Because it takes at least 4 h JPCO, the rate of increase in mean capillary PCO; DF, dilution factor; V CO, CO production. *The subject JB value was not used in this calculated mean, because it deviated more than 2 SD from the mean calculated using the 9 other values. **Mean values of 10 measurements made over 13 mo. for pulmonary uptake or excretion to approach a steady state following a change in V CO (4) . Because the rate of CO excretion is particularly sensitive to alveolar ventilation, the exercise level before the study is critical because a high alveolar ventilation rate will lower COHb and decrease the expired [CO] measured later. Permutt and Pearse (20) have discussed some of these errors that occur when the expired [CO] measurement is made in patients with lung diseases. Expired [CO] correlates with blood COHb levels (16, 23, 30) ; thus an expired [CO] measurement likely produces the same information as obtained from a blood COHb measurement.
The new method described in this paper requires matching of room-tent air and mean capillary PCO to prevent CO excretion and measuring increases in mean capillary PCO resulting from endogenous V CO. Errors involved in using this method to study patients with lung diseases have not yet been determined. Two tests would need to be applied: 1) to determine whether measurements of mean capillary PCO can accurately track a simulated V CO; and 2) to determine the time dependence of equilibrium between mixed alveolar and mean capillary PCO and the most efficient rebreathing protocols to achieve equilibrium.
The method of measuring V CO described here requires control of air PCO in the room-tent. A portable, sealed tent could be smaller than the tent-room utilized in the present study. Current plans are to construct a chamber that can be folded, when not used, into a space 2 ϫ 8 ft. Although currently room-tent air [CO] is controlled by manual CO injections, this could be automated via electronic feedback from the CO analyzer to control CO injections from a tank containing CO, via a solenoid valve, and to trigger brief fan-effected room air mixing.
Conclusions
This study describes and verifies a new method for measuring the rate of endogenous V CO in humans, a measurement that allows calculation of the rate of heme catabolism. It is proposed that this method can be used to study roles of induction of HO-1 in human subjects, to quantify inflammation in terms of the induction of HO-1 and V CO, to study therapeutic approaches including CO therapy, and to quantify hemolysis and effects of therapy in patients with hemolytic anemia. Future approaches for various inflammatory diseases may include genetic approaches to evoke induction of HO-1 in humans, which can be followed with V CO measurements using this method.
APPENDIX
Conversion of V CO as Milliliters Per Hour STPD to moles Heme Catabolized Per Hour
1 mol of a gas ϭ 22,400 ml (STPD). Therefore, 0.43 ml/h/22,400 ϭ 1.92 ϫ 10 Ϫ5 mol heme/h ϭ 19 mol/h.
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